Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats

European Journal of Pharmacology

Volumn 386, Issue 1, 1999, Pages 7-13

  Kosasa, Takashi ^a   Kuriya, Yuka ^a   Matsui, Kenji ^a   Yamanishi, Yoshiharu ^a  

^a EISAI CO LTD   (Japan)

Author keywords

(Rat, aged); (Rat, young); Brain; Cholinesterase inhibitor; Donepezil hydrochloride; E2020; Peripheral tissue; Tacrine

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; TACRINE;

ADOLESCENT; AGE; AGED; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT;

AGING; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; ERYTHROCYTES; INDANS; MALE; PERIPHERAL NERVOUS SYSTEM; PIPERIDINES; RATS; RATS, INBRED F344; TACRINE;

EID: 0033462193     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00741-4     Document Type: Article

References (37)

1. Ambache N., Freeman M.A., Hobbiger F. Distribution of acetylcholinesterase and butyrylcholinesterase in the myenteric plexus and longitudinal muscle of the guinea-pig intestine. Biochem. Pharmacol. 20:1971;1123-1132.
2. Barner E.L., Gray S.L. Donepezil use in Alzheimer disease. Ann. Pharmacother. 32:1998;70-77.
3. Beermann B. Side effects of long acting cholinesterase inhibitor. Acta Neurol. Scand. 149:1993;53-54.
4. Bowen D.M., Smith C.B., White P., Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 99:1976;459-496.
5. Brufani M., Filocamo L., Lappa S., Maggi A. New acetylcholinesterase inhibitors. Drugs of the Future. 22:1997;397-410.
6. Davis P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 2:1976;1403.
7. Drachman D.A. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology. 27:1977;783-790.
8. Edwards J.A., Brimijoin S. Divergent regulation of acetylcholinesterase and butyrylcholinesterase in tissues of the rat. J. Neurochem. 38:1982;1393-1403.
9. Giacobini E. From molecular structure to Alzheimer therapy. Jpn. J. Pharmacol. 74:1997;225-241.
10. Giacobini E. Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem. Int. 32:1998;413-419.
11. Kitagawa H., Fujita S., Suzuki T., Kitani K. Disappearance of sex difference in rat liver drug metabolism in old age. Biochem. Pharmacol. 34:1985;579-581.
12. Leeuwin R.S. Effect of androgenic and anabolic compounds on pseudocholinesterase activity in the liver and serum of the rat. Acta Endocr. 50:1965;391-402.
13. Leeuwin R.S. Effect of testosterone and nandrolone and some of their esters on the pseudocholinesterase activity in the liver and serum and on the seminal vesicle and levator ani muscle of the rat. Acta Endocr. 64:1970;531-540.
14. Leeuwin R.S., Groenewoud E.T. The effect of hepatectomy and sex hormones on the pseudocholinesterase activity in liver and serum of the rat. Acta Endocr. 65:1970;184-192.
15. Meneguz A., Bisso G.M., Michalek H. Age-related changes in acetylcholinesterase and its molecular forms in various brain areas of rats. Neurochem. Res. 17:1992;785-790.
16. Michalek H., Nemesio R., Meneguz A., Bisso G.M. Interactions between anticholinesterase agents and neuroleptics in terms of cholinesterase inhibition in brain and other tissues of rats. Arch. Toxicol., Suppl. 6:1983;386-390.
17. Michalek H., Fortuna S., Pintor A. Age-related differences in brain choline acetyltransferase, cholinesterases and muscarinic receptor sites in two strains of rats. Neurobiol. Aging. 10:1989;143-148.
18. Mihara M., Ohnishi A., Tomono Y., Hasegawa J., Shimamura Y., Yamazaki K., Morishita N. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 31:1993;223-229.
19. Ogura H., Kosasa T., Araki S., Yamanishi Y., Yamatsu K. Behavioral study of E2020, a novel centrally acting acetylcholinesterase inhibitor. Soc. Neurosci. Abstr. 14(1):1988;60.
20. Ohnishi A., Mihara M., Kamakura H., Tomono Y., Hasegawa J., Yamazaki K., Morishita N., Tanaka T. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin. Pharmacol. 33:1993;1086-1091.
21. Perry E.K., Gibson P.H., Blessed G., Perry R.H., Tomlinson B.E. Neurotransmitter enzyme abnormalities in senile dementia: Choline acetyltransferase and glutamic acid decarboxylase in necropsy brain tissue. J. Neurol. Sci. 34:1977;247-265.
22. Perry E.K., Tomlinson B.E., Blessed G., Bergman K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 2:1978;1456-1459.
23. Pintor A., Fortuna S., De Angelis S., Michalek H. Impaired recovery of brain muscarinic receptor sites following an adaptive down-regulation induced by repeated administration of diisopropyl fluorophosphate in aged rats. Life Sci. 46:1990;1027-1036.
24. Rogers S.L., Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicenter open label extension study. Eur. Neuropsychopharmacol. 8:1998;67-75.
25. Rogers S.L., Yamanishi Y., Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. Becker R., Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;314-320 Birkhäuser, Boston, MA.
26. Rogers S.L., Friedhoff L.T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia. 7:1996;293-303.
27. Rogers S.L., Doody R.S., Mohs R., Friedhoff L.T. Donepezil improves cognitive and global function in Alzheimer's disease: a 15-week double-blind, placebo-controlled study. Arch. Intern. Med. 158:1998;1021-1031.
28. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50:1998;136-145.
29. Sastry B.V., Janson V.E., Jaiswal N., Tayeb O.S. Changes in enzymes of the cholinergic system and acetylcholine release in the cerebra of aging male Fischer rats. Pharmacology. 26:1983;61-72.
30. Sherman K.A. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. Becker R., Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;321-328 Birkhäuser, Boston, MA.
31. Sugimoto H., Iimura Y., Yamanishi Y., Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2 yl)methyl]piperidine hydrochloride and related compounds. J. Med. Chem. 38:1995;4821-4829.
32. Thomsen T., Kewitz H., Pleul O. A suitable method to monitor inhibition of cholinesterase activities in tissues as induced by reversible enzyme inhibitors. Enzyme. 42:1989;219-224.
33. Tune L.E., Sunderland T. New cholinergic therapies: treatment tools for the psychiatrist. J. Clin. Psychiatry. 59(supple 13):1998;31-35.
34. Whitehouse P.J. Donepezil. Drugs of Today. 34:1998;321-326.
35. Whitehouse P.J., Price D.R., Struble R.G., Clark A.W., Coyle J.T., Delong M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.
36. Yamanishi Y., Araki S., Kosasa T., Ogura H., Yamatsu K. Neurochemical studies of E2020, a novel centrally acting acetylcholinesterase inhibitor. Soc. Neurosci. Abstr. 14(1):1988;59.
37. Yamanishi Y., Ogura H., Kosasa T., Araki S., Sawa Y., Yamatsu K. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: comparison with other inhibitors. Nagatsu T., Yoshida I. Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Disease. 2:1990;409-413 Plenum, New York, NY.